Top
Summary
All studies
Mortality
Hospitalization
Serious outcomes
Recovery
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
 
Analgesics⏵
Antiandrogens⏵
Antihistamines⏵
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Monoclonals⏵
Mpro inhibitors⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors⏵
TMPRSS2 inh.⏵
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
 
Top
..
All cyproheptadine studies
..
Feedback
Home
c19early.org COVID-19 treatment researchCyproheptadineCyproheptadine (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta
Home Adoption Other Treatments
@CovidAnalysis

Outcomes in COVID-19 cyproheptadine studies

Home
@CovidAnalysis
All
Studies
Feedback
All studies   Mortality   Hospitalization   Serious outcomes   Recovery   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -30% 2 136 Improvement, Studies, Patients Relative Risk Mortality -30% 2 136 Hospitalization -49% 1 40 RCTs -30% 2 136 RCT mortality -30% 2 136 Late -30% 2 136 Cyproheptadine for COVID-19 c19early.org August 2025 Favorscyproheptadine Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Auld (RCT) -51% 1.51 [0.67-3.37] death 35 (n) 61 (n) Improvement, RR [CI] Treatment Control Boniatti (RCT) -11% 1.11 [0.48-2.57] death 7/19 7/21 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.38 Late treatment -30% 1.30 [0.73-2.33] 7/54 7/82 30% higher risk All studies -30% 1.30 [0.73-2.33] 7/54 7/82 30% higher risk 2 cyproheptadine COVID-19 studies c19early.org August 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.38 Effect extraction pre-specified(most serious outcome) Favors cyproheptadine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Auld (RCT) -51% 1.51 [0.67-3.37] 35 (n) 61 (n) Improvement, RR [CI] Treatment Control Boniatti (RCT) -11% 1.11 [0.48-2.57] 7/19 7/21 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.38 Late treatment -30% 1.30 [0.73-2.33] 7/54 7/82 30% higher risk All studies -30% 1.30 [0.73-2.33] 7/54 7/82 30% higher risk 2 cyproheptadine COVID-19 mortality results c19early.org August 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.38 Favors cyproheptadine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Boniatti (RCT) -49% 1.49 [0.94-2.35] hosp. time 19 (n) 21 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.091 Late treatment -49% 1.49 [0.94-2.35] 19 (n) 21 (n) 49% higher risk All studies -49% 1.49 [0.94-2.35] 19 (n) 21 (n) 49% higher risk 1 cyproheptadine COVID-19 hospitalization result c19early.org August 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.091 Favors cyproheptadine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Auld (RCT) -51% 1.51 [0.67-3.37] death 35 (n) 61 (n) Improvement, RR [CI] Treatment Control Boniatti (RCT) -11% 1.11 [0.48-2.57] death 7/19 7/21 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.38 Late treatment -30% 1.30 [0.73-2.33] 7/54 7/82 30% higher risk All studies -30% 1.30 [0.73-2.33] 7/54 7/82 30% higher risk 2 cyproheptadine COVID-19 serious outcomes c19early.org August 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.38 Effect extraction pre-specified(most serious outcome) Favors cyproheptadine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Auld (RCT) -122% 2.22 [1.32-3.85] no recov. 35 (n) 61 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.0036 Late treatment -122% 2.22 [1.32-3.85] 35 (n) 61 (n) 122% higher risk All studies -122% 2.22 [1.32-3.85] 35 (n) 61 (n) 122% higher risk 1 cyproheptadine COVID-19 recovery result c19early.org August 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.0036 Favors cyproheptadine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Auld (RCT) -51% 1.51 [0.67-3.37] death 35 (n) 61 (n) Improvement, RR [CI] Treatment Control Boniatti (RCT) -11% 1.11 [0.48-2.57] death 7/19 7/21 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.38 Late treatment -30% 1.30 [0.73-2.33] 7/54 7/82 30% higher risk All studies -30% 1.30 [0.73-2.33] 7/54 7/82 30% higher risk 2 cyproheptadine COVID-19 Randomized Controlled Trials c19early.org August 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.38 Effect extraction pre-specified(most serious outcome) Favors cyproheptadine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Auld (RCT) -51% 1.51 [0.67-3.37] 35 (n) 61 (n) Improvement, RR [CI] Treatment Control Boniatti (RCT) -11% 1.11 [0.48-2.57] 7/19 7/21 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.38 Late treatment -30% 1.30 [0.73-2.33] 7/54 7/82 30% higher risk All studies -30% 1.30 [0.73-2.33] 7/54 7/82 30% higher risk 2 cyproheptadine COVID-19 RCT mortality results c19early.org August 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.38 Favors cyproheptadine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Auld (RCT) -51% 1.51 [0.67-3.37] death 35 (n) 61 (n) Improvement, RR [CI] Treatment Control Boniatti (RCT) -11% 1.11 [0.48-2.57] death 7/19 7/21 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.38 Late treatment -30% 1.30 [0.73-2.33] 7/54 7/82 30% higher risk All studies -30% 1.30 [0.73-2.33] 7/54 7/82 30% higher risk 2 cyproheptadine COVID-19 peer reviewed studies c19early.org August 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.38 Effect extraction pre-specified(most serious outcome) Favors cyproheptadine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Auld (RCT) -51% 1.51 [0.67-3.37] death 35 (n) 61 (n) Improvement, RR [CI] Treatment Control I-SPY COVID Auld (RCT) -206% 3.06 [1.50-6.24] death/int. 35 (n) 61 (n) I-SPY COVID Auld (RCT) -122% 2.22 [1.32-3.85] no recov. 35 (n) 61 (n) Boniatti (RCT) -11% 1.11 [0.48-2.57] death 7/19 7/21 Boniatti (RCT) -49% 1.49 [0.94-2.35] hosp. time 19 (n) 21 (n) Cyproheptadine COVID-19 outcomes c19early.org August 2025 Favors cyproheptadine Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0